The manufacturer of Zepbound (tirzepatide), Eli Lilly and Co. has released comprehensive findings from Phase 3 trials in the Achieve programme assessing Foundayo (orforglipron), a small-molecule oral GLP-1 used without meal or water restrictions, in individuals with type 2 diabetes.
Foundayo fared better than oral semaglutide on all major secondary objectives in the historic head-to-head Achieve-3 study. Foundayo outperformed dapagliflozin and a placebo added to insulin glargine in tems of A1C reduction and weight loss in Achieve-2 and Achieve-5, respectively, according to Bio Pharm International.
According to a company announcement, Foundayo surpassed oral semaglutide across primary and important secondary endpoints in the Achieve-3 study, the first phase 3 head-to-head comparison of two oral GLP-1 treatments.
Achieve-2, Achieve-3, and Achieve-5 results were presented during the 86th Scientific Sessions of the American Diabetes Association. While Achieve-2 and Achieve-5 were published in The Lancet and JAMA, respectively, the results of Achieve-3 were simultaneously published in The Lancet.
ALSO READ: Covid Pandemic Left 55,000 Cancer Cases Undiagnosed Across 7 Nations, Study Finds
Over 52 weeks, the Achieve-3 study compared two doses of Foundayo with approved oral semaglutide doses in 1,698 people with type 2 diabetes who were not adequately controlled on metformin.
In the maximum-dose comparison, oral semaglutide 14 mg reduced A1C by 1.4%, whereas Foundayo 17.2 mg reduced A1C by an average of 2.2% from a baseline of 8.3%. A1C was reduced by 57.1% as a result of the change. Additionally, the treatment resulted in more weight reduction. Patients who took Foundayo 17.2 mg lost an average of 19.7 pounds, which is 73.6% more than those who took oral semaglutide 14 mg, who lost 11.0 pounds.
Interestingly, compared to 12.5% of patients receiving oral semaglutide, 37.1% of patients getting the higher dose of Foundayo attained an A1C below 5.7%, a threshold typically regarded as within the normal glycemic range.
"Achieve-3 provides the first head-to-head data on oral GLP-1s in type 2 diabetes, with orforglipron showing greater A1C and weight reductions than oral semaglutide," Julio Rosenstock, clinical professor of medicine at the University of Texas.
ALSO READ: Will Artemis III Land On The Moon? Crew Members, Launch Plans, And NASA Mission Update
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
